INS and type 2 diabetes mellitus: Patients with type 2 diabetes received an intrapancreatic autologous bone marrow stem cell infusion; after 1 year, these patients showed improved metabolic control and reduced insulin requirements (Wang et al., 2011; Mathur et al., 2023).